Episode
Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft
- Podcast
- Lung Cancer Update
- Published
- Jul 11, 2026
- Duration seconds
- 3595
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-update-827388/episodes/nonmetastatic-non-small-cell-lung-cancer-an-interview-with-dr-jamie-e-chaft/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-update-827388/nonmetastatic-non-small-cell-lung-cancer-an-interview-with-dr-jamie-e-chaft.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00) Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45) Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39) Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28) Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03) Importance of clinical trials in the adjuvant setting (33:02) Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41) Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34) Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01) CME information and select publications